ClinVar Miner

Submissions for variant NM_177924.5(ASAH1):c.1144G>A (p.Glu382Lys)

gnomAD frequency: 0.00024  dbSNP: rs148976489
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Illumina Laboratory Services, Illumina RCV001163940 SCV001326030 uncertain significance Farber lipogranulomatosis 2017-04-27 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance.
Labcorp Genetics (formerly Invitae), Labcorp RCV001338988 SCV001532700 uncertain significance not provided 2024-01-24 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 382 of the ASAH1 protein (p.Glu382Lys). This variant is present in population databases (rs148976489, gnomAD 0.06%). This variant has not been reported in the literature in individuals affected with ASAH1-related conditions. ClinVar contains an entry for this variant (Variation ID: 911466). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ASAH1 protein function with a negative predictive value of 80%. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Mayo Clinic Laboratories, Mayo Clinic RCV001338988 SCV001713449 uncertain significance not provided 2019-12-27 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV002480573 SCV002791069 uncertain significance Spinal muscular atrophy-progressive myoclonic epilepsy syndrome; Farber lipogranulomatosis 2022-03-29 criteria provided, single submitter clinical testing
CeGaT Center for Human Genetics Tuebingen RCV001338988 SCV004164434 uncertain significance not provided 2023-07-01 criteria provided, single submitter clinical testing ASAH1: PM2:Supporting

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.